leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...4567891011121314...235236»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date, Trial primary completion date:  Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer (clinicaltrials.gov) -  Oct 15, 2024   
    P2,  N=25, Recruiting, 
    SAMe protects against FOLFOX-mediated liver injury in part by inhibiting NF-?B activation and PAI-1 induction. Trial completion date: Jul 2025 --> Apr 2028 | Trial primary completion date: Dec 2024 --> Aug 2027
  • ||||||||||  5-fluorouracil / Generic mfg.
    Clinical, Retrospective data, Review, Journal:  Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis. (Pubmed Central) -  Oct 14, 2024   
    The pooled resection rate after chemotherapy switch was 42% and similar in overall survival compared with first-line chemotherapy only. Three ongoing trials are investigating chemotherapy switch in patients with an inadequate radiological or carbohydrate antigen 19-9 response.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., paclitaxel / Generic mfg.
    Intraperitoneal paclitaxel plus systemic FOLFOX for gastric cancer with peritoneal metastasis  (Poster in Spotlight booth 1) -  Oct 13, 2024 - Abstract #ESSO2024ESSO_148;    
    Conversion surgery was performed in 9 patients (40.9%) with 2 patients achieving complete remission of tumor. Port-related complications occurred in 4 (18.2%) patients and all underwent conservative management.Conclusions (For Surgical Trial in Progress and Surgical Trial Proposals fill in 'NA') The biweekly regimen of IP paclitaxel and FOLFOX showed tolerable toxicity and demonstrated promising efficacy in terms of survival rates compared to standard treatment.
  • ||||||||||  leucovorin calcium / Generic mfg.
    NALIRIFOX in advanced pancreatic cancer: An exploratory real-world analysis (Boston) -  Oct 13, 2024 - Abstract #DGHO2024DGHO_1524;    
    To the best of our knowledge this is the first real-world analysis of NALIRIFOX in unresectable or metastatic pancreatic cancer. Efficacy results confirm the phase NAPOLI 3 trial while holding promising safety.
  • ||||||||||  5-fluorouracil / Generic mfg.
    CHEMOTHERAPY-INDUCED PNEUMATOSIS INTESTINALIS IN GASTROESOPHAGEAL CANCER () -  Oct 11, 2024 - Abstract #ASCOMOS2024ASCOMOS_296;    
    Cytotoxic chemotherapy induces GI mucosal damage, which could lead to PI. With advancements in systemic cancer therapy, understanding the mechanisms of PI behind different therapies is essential.
  • ||||||||||  Vyloy (zolbetuximab) / Astellas
    FINAL OVERALL SURVIVAL IN PHASE 3 SPOTLIGHT: ZOLBETUXIMAB + mFOLFOX6 IN CLDN18.2+ HER2? ADVANCED GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA () -  Oct 11, 2024 - Abstract #ASCOMOS2024ASCOMOS_281;    
    METHODS Patients were randomized 1:1 to zolbetuximab IV 800 mg/m2 (C1D1) followed by 600 mg/m2 (every 3 weeks) + mFOLFOX6 IV (D1, D15, D29) for four 42-day cycles or placebo + mFOLFOX6; patients without PD continued with zolbetuximab or placebo, + folinic acid and 5-FU (investigator's discretion), until PD or discontinuation criteria were met...Safety/tolerability were maintained (no new findings). CONCLUSIONS Zolbetuximab + mFOLFOX6 continued to demonstrate significant improvement in PFS/OS vs placebo + mFOLFOX6, with no new safety signals
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    MULTIMODALITY TREATMENT APPROACH IN A PATIENT WITH METASTATIC COLON ADENOCARCINOMA () -  Oct 11, 2024 - Abstract #ASCOMOS2024ASCOMOS_274;    
    FOLFIRI and cetuximab was given prior to surgery, with good biochemical and radiological response...Selective peritonectomy, extrafascial hysterectomy with bilateral salpingo-oophorectomy (EHBSO), left ureterectomy and nephrectomy, plus HIPEC with mitomycin C was performed in September 2023, without complications...Post-operatively, the patient received maintenance therapy with capecitabine and cetuximab from October 2023 till now...Multidisciplinary team discussion and pre-operative work up are crucial. While the aim of multimodality approach is to maximize treatment options, careful selection of cases is essential to achieve the best results in terms of survival outcome and patients' quality of life.
  • ||||||||||  5-fluorouracil / Generic mfg.
    CHEMOTHERAPY: THE UNLIKELY HERO IN OVERCOMING HCC RESISTANCE. A CASE REPORT () -  Oct 11, 2024 - Abstract #ASCOMOS2024ASCOMOS_217;    
    However, after 3 cycles of Lenvatinib, her AFP persistently increased, leading to a switch to Atezolizumab-Bevacizumab...The shift to FOLFOX chemotherapy post-prior treatment failure, highlights the need of flexibility in patient care. Essentially, this and showcases the importance of personalized approach to optimize patient outcome.
  • ||||||||||  oxaliplatin / Generic mfg.
    Journal:  Safety outcomes of rapid- versus standard-infusion rate oxaliplatin. (Pubmed Central) -  Oct 10, 2024   
    Rapid-rate oxaliplatin was associated with minimal treatment modifications; however, there was an increase in PN incidence. A faster rate of oxaliplatin administration may not be worth the increased risk of PN.
  • ||||||||||  Trial primary completion date:  PANCREAS: Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery (clinicaltrials.gov) -  Oct 10, 2024   
    P2,  N=30, Recruiting, 
    A faster rate of oxaliplatin administration may not be worth the increased risk of PN. Trial primary completion date: May 2024 --> Dec 2025
  • ||||||||||  Avastin (bevacizumab) / Roche, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Oct 9, 2024   
    P2,  N=173, Recruiting, 
    Exploration of patient preferences and resource costs may improve adoption of reduced duration adjuvant CAPOX in stage III CRC. Not yet recruiting --> Recruiting | N=50 --> 173 | Trial completion date: Dec 2025 --> Mar 2027 | Trial primary completion date: Dec 2024 --> Feb 2026
  • ||||||||||  oxaliplatin / Generic mfg., capecitabine / Generic mfg.
    Enrollment change, Trial termination:  PECORINO: Perioperative Chemotherapy in Gastric Cancer (clinicaltrials.gov) -  Oct 8, 2024   
    P2,  N=69, Terminated, 
    Aflibercept?+?FOLFIRI could be effective in controlling metastasis of RAS mutant colon cancer even after treatment with bevacizumab. N=284 --> 69 | Active, not recruiting --> Terminated; High rate of disease progression in XELOX arm
  • ||||||||||  oxaliplatin / Generic mfg.
    Journal:  Oxaliplatin Antibody-Related Thrombocytopenia: A Case Report. (Pubmed Central) -  Oct 7, 2024   
    She was treated with platelet transfusion, intravenous immunoglobulin, and steroids for concerns of immune thrombocytopenia; however, through the use of flow cytometry, oxaliplatin and leucovorin antibodies were discovered. Ultimately, oxaliplatin was permanently discontinued due to concerns about further events of thrombocytopenia.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    TGFB2 mRNA levels prognostically interact with interferon-alpha receptor activation of IRF9 and IFI27, and makers for tumor-associated macrophages impacting overall survival in PDAC (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1716;    
    Background The treatment of pancreatic ductal adenocarcinoma (PDAC) is an unmet challenge, with the median overall survival rate remaining less than a year, even with the use of FOLFIRINOX-based therapies...Conclusions The results of our study suggest that a combination of pharmacological tools can be used in treating PDAC patients, targeting both TGFB2 and the components of the type-I interferon signaling pathway to improve OS outcomes. TGFB2 expression impacts OS independent of TAM markers, but the expression of TAM markers impacts the prognostic effect of TGFB2 mRNA expression.
  • ||||||||||  etrumadenant (AB928) / Arcus Biosci, Gilead
    The adenosine receptor antagonist etrumadenant reduces tumor adenosine-regulated NR4A gene expression and increases mCRC inflammation in patients from the ARC-9 trial (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1588;    
    P1/2
    Etruma, in combination with zimberelimab (Z) (anti-PD-1 antibody), FOLFOX, and bevacizumab (bev) (EZFB regimen) demonstrated an impressive overall survival (OS) benefit compared to the regorafenib (rego) control arm in third-line, chemo-resistant mCRC in the primary analysis of the ARC-9 study (NCT04660812)...Consistent with an adenosine-targeting MoA, EZFB provided significantly improved PFS and OS compared to rego for patients with CD73 IHC-positive tumors. Ethics Approval All patients were provided the most recent copy of the Informed Consent form describing the study and associated interventions, which the patient or their legally authorized representative were required to sign and date prior to participating in the study.
  • ||||||||||  magrolimab (ONO-7913) / Ono Pharma
    Myeloid checkpoint CD47 protein is elevated in CRC liver metastases compared to primary tumors and correlates with phagocytic macrophage proportions (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1214;    
    Anti-CD47 antibodies such as Magrolimab have the potential to promote phagocytosis of cancer cells...The enrichment of phagocytic C1QC to angiogenic SPP1 TAMs in the liver is associated with CD47 up-regulation possibly suggesting greater evasion of macrophage mediated immune surveillance in the liver. Future studies are needed to further understand the relationship between CD47 expression, tissue microenvironment and clinical efficacy of anti-CD47 antibodies in liver metastases vs. primary tumors.Download figure Open in new tab Download powerpoint Abstract 523 Figure 1 CRC liver metastases show significantly higher CD47 staining than primary CRC tumors
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Evaluation of a Folic Acid Wound Treatment (FAWT) for Chronic, Early-Stage Diabetic Foot Ulcer (DFU) Healing (clinicaltrials.gov) -  Oct 4, 2024   
    P2,  N=15, Completed, 
    Ethics Approval The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines as defined by the International Conference on Harmonisation, in 14 European University Hospitals according to the study protocol and amendments, approved by local Institutional Review Boards and independent ethics committees: France:Comit Recruiting --> Completed | N=30 --> 15 | Trial primary completion date: Dec 2023 --> Sep 2024
  • ||||||||||  Journal:  Urachal carcinoma initially presenting only as a liver metastasis, a diagnostic and therapeutic challenge: first case in literature. (Pubmed Central) -  Oct 3, 2024   
    Finally, the patient received two doses of FOLFIRI-B with no response and kept deteriorating and died after 19 months of treatment...Also, our study presents the first attempt of using FLOFIRI-B to treat metastatic UraC. This case highlights the necessity for clinicopathological correlation to make the correct diagnosis and the challenges in the treatment which urges the need for further research to identify more effective treatment strategies for this rare cancer.
  • ||||||||||  leucovorin calcium / Generic mfg.
    Journal, Metastases:  FDA endorses NALIRIFOX for metastatic pancreatic adenocarcinoma: an editorial. (Pubmed Central) -  Oct 3, 2024   
    This case highlights the necessity for clinicopathological correlation to make the correct diagnosis and the challenges in the treatment which urges the need for further research to identify more effective treatment strategies for this rare cancer. No abstract available